An ongoing dialogue on HIV/AIDS, infectious diseases,
May 2nd, 2010
Learning from Clinical Trials with Limited “Generalizability”
In the ongoing debate about when to start antiretroviral therapy in our sickest patients — those with acute opportunistic infections — comes this study from Zimbabwe of early vs. deferred ART in patients with cryptococcal meningitis:
The median durations of survival were 28 days and 637 days in the early and delayed ART groups, respectively (P
=
.031, by log‐rank test). The risk of mortality was almost 3 times as great in the early ART group versus the delayed ART group (adjusted hazard ratio, 2.85; 95% confidence interval, 1.1–7.23). The study was terminated early by the data safety monitoring committee.
In sum, early ART made a terrible situation even worse: 3-year survival for the early ART group was only 22%, vs 46% in the deferred therapy group.
The challenges of applying this study to clinical practice here are numerous, including use of non-amphotericin therapy for cryptococcal CNS disease, lack of protocol-directed management of suspected raised intracranial pressure or immune reconstitution inflammatory syndrome (IRIS), and the highly unstable social and political situation in the country at that time.
Still — sometimes a study’s findings are so overwhelming that that there is something to be learned, issues of limited generalizabilty notwithstanding.
I suspect here it’s that ART should be deferred for at least a couple of weeks in patients with crytpotoccal meningitis, giving the amphotericin/5FC time to bring down the organism burden. Importantly, this slight delay would still be consistent with the “early” ART strategy of A5164, where the median time to start therapy was 12 days after OI treatment.
At least that’s what I’ll be doing until the results of this study are available.
Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
FROM NEJM — Recent Infectious Disease Articles- The Invisible Load of Cognitive Symptoms July 2, 2026Patients with shrinking cognitive bandwidth may feel their disability keenly in daily life, even if they can pass a controlled test of cognitive capacity. How should clinicians approach and care for them?
- Cat Scratch Disease July 2, 2026A 40-year-old woman presented with a 1-month of history of fevers and 3-week history of swelling in her right armpit. Ultrasonography showed enlarged lymph nodes with an adjacent fluid collection.
- Operative versus Nonoperative Management for Appendicitis July 2, 2026This feature about treatment of appendicitis offers a case vignette accompanied by two essays, one recommending operative management and the other supporting a nonoperative approach.
- Advances in Multiple Sclerosis July 2, 2026This review summarizes advances in the treatment of multiple sclerosis, with emphasis on effective disease-modifying therapies for relapsing disease and the need for better treatments to prevent progression and rebuild myelin.
- Ebola at 50 — Lessons for Outbreak Response and Preparedness July 1, 2026An accurate history of Ebola begins with partnerships, including those between responders and the populations they serve. One of its key lessons is that equity must be integral to outbreak preparedness.
- The Invisible Load of Cognitive Symptoms July 2, 2026